We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Two doses of the Johnson & Johnson (J&J) COVID-19 vaccine (Ad26.COV2.S) cut the risk of a COVID-related hospitalization by 85 percent, the company has reported — and the benefit may be coming from ramped-up T-cells rather than vaccine-induced antibodies. Read More
The paper, posted on the MedRxiv.com preprint server, found that Omicron infection increased immunity against Omicron reinfection by 14-fold and immunity against Delta by 4.4-fold. Read More
In terms of approvals of new products, 2021 was the second-best year for cell and gene therapies and tissue products (The best year was 2016, when nine therapies were approved.). Read More
People vaccinated against COVID-19 who get an Omicron infection appear to have a low risk of Omicron reinfection, as well as significantly increased resistance to the Delta variant, new South African data suggest. Read More
CEPI, the Coalition for Epidemic Preparedness Innovations, has joined with Korean biopharma firm SK Biopharma (SK) to develop a “variant-proof” vaccine that would protect against a large coronavirus subgenus that includes the SARS-CoV-2 virus that causes COVID-19. Read More
Eli Lilly’s IL-13 inhibitor lebrikizumab significantly improved disease severity when combined with topical corticosteroids in people with moderate-to-severe atopic dermatitis (AD) in the drug’s third pivotal phase 3 trial, the company said. Read More
Both companies cited the “Open Data Portal SARS-CoV-2 Variants and Therapeutics Activity Explorer,” hosted by the National Center for Advancing Translational Science. Read More
Ligelizumab, Novartis’ investigational anti-IgE antibody, didn’t stand up to the company’s established blockbuster omalizumab in a pair of phase 3 studies in patients with chronic spontaneous urticaria (CSU). Read More